Retrospective Study on Agitation Provoked by Memantine in Dementia
Abstract
The authors retrospectively reviewed the clinical records of 196 patients with dementia treated with memantine for at least 6 months. Eleven (5.6%) developed treatment-induced agitation. At chi-square analysis, they were significantly more likely to have a history of similar side effects from other medications acting on the central nervous system in comparison with the group without agitation, suggesting neurochemical susceptibility. A trend toward a significantly greater prevalence was also present for ischemic cardiopathy and neuroimaging evidence of chronic small vessel disease. Ischemic brain and heart disease might contribute through anatomical and functional alterations within the glutamatergic system.
The N-methyl-d-aspartic acid (NMDA) receptor antagonist memantine (Ebixa; Lundbeck Canada, Montreal, Canada) has demonstrated efficacy against the development of agitation and aggressiveness in Alzheimer’s disease (AD),1–3 hypothetically via correction of glutamate transmission and reduction of tangle formation in the frontal and cingulate cortices.4,5 Conversely, memantine has been shown to cause agitation and other psychotic manifestations. A total of 11 cases of AD,6,7 Lewy body disease,8–10 and Parkinson’s disease11 have been reported who developed agitation, hallucinations, delusions, and intense dreaming after a few doses and recovered at drug withdrawal. This apparently paradoxical effect of memantine has a neurochemical plausibility. The NMDA hypofunction within the limbic system is deemed to underlie psychotic disorders,5 and psychotic symptoms are a known side effect of other glutamate receptor antagonists such as amantadine and phencyclidine.
In the present study, we retrospectively reviewed the clinical records of a large sample of patients with dementia treated with memantine, with the aim to measure the prevalence of treatment-emergent agitation in naturalistic conditions and identify possible clinical correlates of this puzzling effect of the drug.
Patients and Methods
Participants were enrolled from the memory clinic of S. Gerardo Hospital, Monza, Italy. They were consecutive patients started on memantine between January 2008 and December 2010 and followed up for at least 6 months since therapy onset. Criterion for inclusion was a diagnosis of dementia according to DSM IV criteria.12 The study had the relevant institutional ethical approval and complied with the Declaration of Helsinki.
As prescribed in the drug instruction sheet, the maximum daily dose of 20 mg was usually achieved by upward titration of 5 mg/week over a period of 3 weeks.
Agitation, restlessness, irritability, and aggressiveness reported by patients or informants were all recorded as agitation; co-occurrence of confusion, hallucinations, and delusions was also taken into account. The symptoms were deemed to be drug related when they developed de novo or worsened if already present at study entry, in temporal relationship with treatment start or increase, and resolved after dose reduction or withdrawal.
The following characteristics of patients with (A+) and without (A−) memantine-related agitation were compared using two-tailed Student’s t or chi-square tests: percentage of AD and non-AD diagnoses; Mini Mental State Examination (MMSE) score; presence of neuropsychiatric disturbances at treatment onset; previous episodes of agitation caused by other drugs; type and frequency of comorbidities; distribution of concurrent medications; evidence of chronic small vessel disease at the visual rating of brain CT or MRI scans by the neuroradiologist. The level of significance was set at p<0.05, and Bonferroni correction for multiple comparisons was applied. Statistical analysis was performed with PASW statistics, Release Version 18.0.0 (SPSS, Chicago, IL).
Results
A total of 209 cases meeting inclusion criteria were identified, but 13 had to be excluded due to inadequate data. Of the 196 cases included in the final sample, 11 (5.6%) showed memantine-related agitation, and their demographic and clinical features are shown in Table 1.
Patient N | Sex/Age-Diagnosis | MMSE Score | Description of Event |
---|---|---|---|
1 | F/83–AD | 9 | Preexisting agitation worsens soon after the first 5-mg doses. The treatment is withdrawn after 1 week at 10 mg. |
2 | F/83–AD | 10 | The patient shows progressive exacerbation of agitation during memantine titration. The treatment is discontinued after a few days at 20 mg. |
3 | F/77–AD | 14 | Due to an error in following the prescription, the dose of memantine is maintained at 10 mg for 6 months. The increase to 20 mg causes agitation and confusion within a couple of days, and the dose is brought back to 10 mg. |
4 | M/66–AD | NA | The patient is agitated and aggressive at treatment start, and gradually worsens during memantine increase up to 20 mg. The drug is discontinued approximately after 5 weeks since its introduction. |
5 | M/81–AD | 19 | De novo agitation develops immediately after the first 5-mg doses. The drug is withdrawn after 1 week at 10 mg. |
6 | M/81–AD | 21 | The patient is mildly agitated at treatment start and remains stable up to 10 mg of memantine. A few days at 20 mg cause severe agitation and the dose is reduced. Preexisting hallucinations and delusions remain unchanged. |
7 | M/85–AD | 21 | The patient becomes increasingly agitated and confused during the titration to 20 mg, and the treatment is discontinued within a few weeks. |
8 | F/96–AD | 13 | Progressive confusion and exacerbation of agitation occur since treatment start. The drug is withdrawn after 1 week at 15 mg. Preexisting hallucinations and delusions are apparently unchanged. |
9 | M/77–AD | 9 | Agitation and confusion develop within the first days at 5 mg, and treatment is discontinued 10 days later. |
10 | M/63–PCA | 9 | Preexisting agitation worsens after less than 1 week at 20 mg, and memantine is discontinued 20 days later. |
11 | M/74–LBD | 20 | Agitation and de novo visual hallucinations develop soon after the increase to 10 mg. The treatment is discontinued 10 days after its introduction. |
TABLE 1. Characteristics of Patients Who Developed Agitation as an Adverse Event of Treatment With Memantinea
The remaining 185 patients were 70 men (38%) and 115 women, with a mean age of 77.3±8.0 years and a mean MMSE score of 16.9±5.0 and had the following diagnoses, based on current criteria13–18: AD (n=113, 61%), vascular or mixed dementia (n=21, 11%), Lewy body dementia (n=16, 9%), fronto-temporal dementia (n=13, 7%), corticobasal degeneration (n=8, 4%), nonotherwise specified dementia (n=8, 4%), and posterior cortical atrophy (n=6, 3%). Within this A− group, 148 patients (80%) showed mild (n=71, 38%) or moderate to severe (n=77, 42%) behavioral disturbances at the time they were started on memantine. After 2.1±1.1 years of treatment on average, an improvement of agitation was reported by the clinician, based on informants’ reports, for 28 cases (19%).
A brief description of the adverse events with memantine is reported in Table 1. In five of 11 (45.5%) patients, agitation developed de novo, whereas in the other six patients, it was preexisting and worsened after drug introduction. In four cases (36.4%), it was associated with confusion, and in one patient (9.1%), it was associated with de novo visual hallucinations. The adverse effects became evident after the first doses in seven cases (63.6%) and when the daily dose was increased to 10 mg or above in the other four patients. Memantine was reduced to 10 mg/day in two cases (18.2%) and was withdrawn in all the others, with a complete remission of the adverse effects within a few days. No A+ patient completed more than 2 weeks at 20 mg. In case 7, the drug was tentatively reintroduced 18 months later, with a slower increase to 20 mg, but again had to be discontinued due to agitation and confusion.
Within the study follow-up period (2.2±1.0 years on average), a total of 22 adverse effects tentatively attributed to memantine were also observed in the A− group, the most frequent (3.6%) being a vague feeling of “being unwell” (Table 2). Because of these side effects, treatment was withdrawn or reduced in 20 (10.2%) cases. Discontinuation also occurred in 45 (23%) other A− patients for reasons other than adverse events, e.g., disease progression (Table 3). The mean duration of treatment was 2.0±1.2 years for the A− group (range: 1 month to 5.3 years).
Variable | N | Percentage |
---|---|---|
Adverse events | ||
Aspecific malaise | 7 | 3.6 |
Dizziness | 4 | 2.0 |
Sedation | 4 | 2.0 |
Asthenia | 2 | 1.0 |
Hypertension | 2 | 1.0 |
Constipation | 2 | 1.0 |
Chronic cough | 1 | 0.5 |
Total | 22 | 11.2 |
Causes of discontinuation | ||
Disease progression | 17 | 8.7 |
Institutionalization | 12 | 6.1 |
Medical or surgical conditions (unrelated to memantine) | 7 | 3.6 |
Unknown | 4 | 2.0 |
Total | 45 | 23.0 |
TABLE 2. Adverse Events of Memantine and Causes of Discontinuation Other Than Treatment Side Effects in the Group of 185 Patients Who Did Not Develop Agitation
Patients With Agitation (N=11) | Patients Without Agitation (N=185) | t test/χ2 | p | |
---|---|---|---|---|
Age (mean±SD) | 79.1±8.6 | 77.3±8.0 | –0.680 | 0.511 |
Sex (men) | 63.6% | 37.8% | 2.897 | 0.085 |
MMSE (mean±SD) | 14.5±5.3 | 16.9±5.0 | –1.395 | 0.193 |
Dementia of the Alzheimer typeb | 91.0% | 68.1% | 2.541 | 0.098 |
Preexisting BPSD | 63.6% | 81.6% | 2.149 | 0.142 |
Cerebral chronic small vessel disease | 36.4% | 6.5% | 12.363 | 0.007 |
Ischemic cardiopathy | 37.6% | 6.5% | 12.363 | 0.007 |
Agitation with past medications | 36.4% | 2.8% | 26.205 | 0.001 |
Concomitant AChE inhibitors | 36.4% | 37.3% | 0.004 | 0.610 |
Drugs active on the CNSc | ||||
Antidepressants | 92.9% | 79.9% | 1.607 | 0.182 |
Antipsychotics | 43.9% | 40.0% | 0.897 | 0.684 |
Others | 23.0% | 33.0% | 2.001 | 0.132 |
Other medications | ||||
Antihypertensives | 65.5% | 53.2% | 2.648 | 0.165 |
Cardiological drugs | 54.6% | 36.2% | 1.980 | 0.155 |
Cholesterol lowering drugs | 45.5% | 24.6% | 3.238 | 0.100 |
Antidiabetics | 18.2% | 9.7% | 0.809 | 0.311 |
Others | 35.7% | 36.7% | 0.041 | 0.599 |
Treatment with more than one drug | 90.9% | 87.0% | 0.141 | 0.578 |
History of stroke/TIA | 9.1% | 5.9% | 0.179 | 0.510 |
Non vascular neurological disorders | 9.1% | 10.3% | 0.016 | 0.689 |
Vascular risk factorsd | 90.9% | 58.4% | 4.586 | 0.028 |
Cancer | 9.1% | 10.3% | 0.016 | 0.689 |
Atrial fibrillation | 54.5% | 16.2% | 10.173 | 0.006 |
Other heart-diseasese | 0.0% | 3.2% | 0.368 | 0.704 |
Lung diseases | 9.1% | 6.5% | 0.114 | 0.540 |
Digestive system diseases | 45.5% | 14.6% | 7.238 | 0.019 |
Other comorbidities | 36.4% | 23.2% | 0.980 | 0.255 |
TABLE 3. Demographic and Clinical Features of the 11 Patients Who Developed Agitation as an Adverse Effect of Memantine Compared With the Rest of the Study Populationa
Results of comparison analysis for demographic and clinical features of A+ and A− patients are shown in Table 3. After Bonferroni correction, a statistically significant difference (p=0.001) was found for a greater frequency, in the A+ group, of past episodes of agitation in response to other drugs (rivastigmine in one patient, donepezil in another case, donepezil and citicoline in a third patient, and piracetam in one last case). A strong trend toward significance was present for a higher prevalence of brain small vessel disease and ischemic cardiopathy (36.4% versus 6.5%, p=0.007, for both), whereas no difference emerged in the distribution of related medications. There was no case of overlap of the three more significant variables in the A+ group; only one of four patients with cerebrovascular disease also showed ischemic cardiopathy, and only two of four patients taking anticholinesterase inhibitors also showed one of the two disorders. This suggests an independent contribution for the three features.
The 28 cases who showed improvement in behavioral disturbances after starting memantine did not differ from the A+ group for the following features: age, gender, education, distribution of diagnoses, disease duration, MMSE score, percentage of patients treated with anticholinesterase inhibitors or other neuropsychiatric drugs, and prevalence of non-neurological comorbidities or treatments (data not shown). A trend toward significance was only present for a higher proportion of A+ cases showing brain small vessel disease at neuroimaging (36.4% versus 7.1%, p=0.042).
Discussion
The retrospective nature of our study and the lack of structured measures of safety (e.g., a neuropsychiatric scale) did not allow a systematic, fine-grained, and standardized collection of data. Moreover, being unblinded to treatment, we may have been biased in establishing a causal relationship between memantine and agitation. Also, the absolute number of cases showing the adverse effects was small and allowed only an exploratory analysis of features comparisons. Finally, errors in the presumed clinical diagnoses cannot be ruled out, and might have affected our results because the underlying pathological diagnosis may be a risk factor for the development of memantine-induced agitation.
On the other hand, the entire study population was relatively large and was studied in a naturalistic setting, which guarantees a realistic and clinically relevant depiction of the event under investigation. Therefore, we believe that useful indications for future studies may come from our results, along with some hint for clinical practice.
In particular, we highlighted some feature that may help dementia specialists to identify patients at risk of developing neuropsychiatric side effects of memantine. A red flag seems to be a history of agitation in reaction to brain enhancers. Informants should be specifically inquired about that before treatment start. Evidence of chronic microvascular changes at neuroimaging and presence of coronary heart disease (more precisely, a history and/or electrocardiographic or echocardiographic evidence of miocardial infarction) should also be taken into account, whereas preexisting agitation and concomitant medications do not necessarily entail a more careful monitoring of the patient once he/she is started on memantine.
The fact that A+ patients showed the same side effects in response to other medications acting on the central nervous system suggests that some subject might have a neurochemical predisposition to develop the adverse event. Following the glutamate model of psychosis,5 it could be hypothesized that a low baseline glutamatergic tone might make them more vulnerable to the psychosis-inducing effect of the NMDA antagonist. Cerebrovascular damage and ischemic cardiopathy are known to cause anatomical and functional changes in the brain.19 Such changes might also decrease NMDA transmission. Finding a biochemical account for memantine-related agitation is anyway beyond the scope and possibilities of our work and will have to be addressed in future studies.
Upcoming investigations should also explore clinical differences between patients with the adverse event and those with the opposite effect, i.e., with a positive impact of memantine on the development of agitation. In the present study, we could only explore the prevalence (6%) of improvement in preexisting agitation informally, in unblinded conditions, and without controlling for the contribution of concomitant neuropsychiatric drugs. In clinical trials,1,2 agitation is reported in 7%−8% of patients treated with memantine. According to our results, only a minority of these cases can be classified as nonresponders who do not benefit from the preventive effect of the drug on behavioral disturbances. Most of them are actually experiencing an adverse event, which, being disturbing and reversible with drug withdrawal, imposes therapy discontinuation. Given the limited options of treatment available for patients with dementia, the impact of this phenomenon on their prognosis and management can be very heavy.
1 : Memantine for dementia. Cochrane Database Syst Rev 2006; 2:CD003154Google Scholar
2 : Behavioral effects of current Alzheimer’s disease treatments: a descriptive review. Alzheimers Dement 2008; 4:49–60Crossref, Medline, Google Scholar
3 : Memantine for the treatment of Alzheimer’s disease: tolerability and safety data from clinical trials. Drug Saf 2008; 31:577–585Crossref, Medline, Google Scholar
4 : Altered glutamate neurotransmission and behaviour in dementia: evidence from studies of memantine. Curr Mol Pharmacol 2009; 2:77–82Crossref, Medline, Google Scholar
5 : NMDA neurotransmission dysfunction in behavioral and psychological symptoms of Alzheimer’s Disease. Curr Neuropharmacol 2012; 10:272–285Crossref, Medline, Google Scholar
6 : Development of subtle psychotic symptoms with memantine: a case report. J Clin Psychiatry 2005; 66:658–659Crossref, Medline, Google Scholar
7 : Visual hallucinations and agitation in Alzheimer’s disease due to memantine: report of three cases. J Neurol Neurosurg Psychiatry 2007; 78:546Crossref, Medline, Google Scholar
8 : Delusions and hallucinations in dementia with Lewy bodies: worsening with memantine. Neurology 2005; 65:481–482Crossref, Medline, Google Scholar
9 : Memantine-related psychotic symptoms in a patient with bipolar disorder. J Clin Psychiatry 2010; 71:957Crossref, Medline, Google Scholar
10 : Exacerbation of Lewy bodies dementia due to memantine. J Alzheimers Dis 2005; 8:289–291Crossref, Medline, Google Scholar
11 : Pharmacotoxic psychosis after memantine in Parkinson’s disease. Lancet 1991; 338:1022–1023Crossref, Medline, Google Scholar
12 American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC, American Psychiatric Association, 2000Google Scholar
13 : The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7:263–269Crossref, Medline, Google Scholar
14 : Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993; 43:250–260Crossref, Medline, Google Scholar
15 : Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65:1863–1872Crossref, Medline, Google Scholar
16 : Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998; 51:1546–1554Crossref, Medline, Google Scholar
17 : Criteria for the diagnosis of corticobasal degeneration. Neurology 2013; 80:496–503Crossref, Medline, Google Scholar
18 : The cognitive profile of posterior cortical atrophy. Neurology 2006; 66:331–338Crossref, Medline, Google Scholar
19 : Cognitive and brain changes associated with ischaemic heart disease and heart failure. Eur Heart J 2012; 33:1769–1776Crossref, Medline, Google Scholar